Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Cd4 receptors" patented technology

A protein found primarily on the surface of CD4 T lymphocytes (CD4 cells). To enter a host cell, HIV binds to a CD4 receptor and a coreceptor (either CCR5 or CXCR4) on the host cell.

Gene sequence construct for gene therapy for HIV infection

The present invention relates to a gene sequence construct for gene therapy for HIV infection. The gene sequence construct is constructed by means of sequentially connecting, via a coding sequence of a linker polypeptide, a gene coding sequence of a variable region scFv in each light chain and heavy chain of a monoclonal antibody against antigens at different binding sites involved in the different steps of HIV infection of a human CD4+ T cell, a gene coding sequence of a variable region scFv in each light chain and heavy chain of a monoclonal antibody bound to a human CD4 receptor site, a gene coding sequence of an Fc fragment in a human IgG constant region, and a gene coding sequence of a polypeptide for inhibiting the fusion of HIV and a CD4+ T cell membrane, and by placing the connected gene coding sequences downstream of a promoter and a secretion signal peptide coding sequence, thereby expressing a single-gene-encoded secretion-type antibody-like protein molecule. The recombinant single-gene construct can be conveniently introduced into a target tissue cell via a viral vector, and the expressed secretion-type antibody-like protein molecule has multi-antigen tropism, can realize the efficient and broad-spectrum blockade of the HIV infection process on a human CD4+ T cell by means of binding to multiple binding sites involved in the different steps of HIV infection of the human CD4+ T cell, and effectively avoids the loss of the ability to inhibit an HIV infection due to an HIV escape mutation, thereby achieving a long-term or even permanent treatment effect on HIV infection by means of a single injection.
Owner:KANGLIN BIOTECHNOLOGY (HANGZHOU) CO LTD

A multispecific and / or multivalent binding protein for preventing and / or treating HIV infection

PendingCN122444879ADiseaseBinding site
The present application relates to a kind of multispecific and / or multivalent binding protein for preventing and / or treating HIV infection, it includes at least 3 antigen binding sites, part of antigen binding site is specifically bound HIV-1-gp41 or HIV-1-gp120 or HIV-1-gp160, still part of antigen binding site is specifically bound human CD4 receptor or human CCR5 receptor;The binding protein of the present application has excellent broad-spectrum neutralizing ability in the treatment or prevention of HIV infection, provides a new solution for the problem of drug resistance escape caused by HIV virus variation, in addition, the present application inventor also unexpectedly found that the binding protein of the present application can treat or prevent the tumor-related disease caused by HIV infection.
Owner:FUDAN UNIVERSITY

An HIV inhibitor

The present invention discloses a HIV inhibitor, which is a compound prepared by condensing BHA-Lys-Lys2-Lys4-Lys8-Lys16-32TFA and a capping group compound protected by tert-butyloxycarbonyl, and then removing the tert-butyloxycarbonyl protecting group. The compound shows in an in vitro anti-HIV-1 activity test that the compound has good solubility and anti-HIV-1 activity, and has no obvious cytotoxicity. In addition, the compound is based on simulating the CD4 receptor binding to the gp120 key domain Phe43 cavity, achieving antiviral effects on the key protein specific binding of the virus invading the cell. The compound can not only greatly avoid the disadvantage that the polyanionic polymer will promote the formation of amyloid fibers in semen, but also because it is a macromolecule, the transdermal effect is poor and it will not be absorbed by the mucous membrane into the blood circulation.
Owner:REGENEX PHARMA LTD